The proposed developmental funds constitute an invaluable flexible funding source for the UCCC to pursue the initiatives and research opportunities identified though the planning and evaluation activities of the Cancer Center. The UCCC proposes to use these funds to 1) strengthen scientific programs, 2) support faculty recruitment in areas of strategic focus and need, 3) provide both junior and more established investigators the opportunity to explore research ideas of particular innovation and collaboration through pilot grant program funds, and 4) support the development of two new shared resources. Specifically, the UCCC proposes to allocate $200K per year in support of recruitment for seven faculty: Associate Director for Basic Science;senior breast and prostate cancer investigator;senior bladder cancer biologist;senior metastasis investigator and senior immunologist for the developing Metastasis and Tumor Microenvironment Program;and Program Co-leader for Cancer Cell Biology. An annual budget of $200K is proposed in support of the broad-based and diverse UCCC Pilot Grant Programs. A budget of $100K is proposed for each of two developing shared resources: 1) Preclinical Animal Services SR and 2) Human Research Imaging. Funding for these proposed projects totals $600K per year. For all categories of the request, the proposed funds will be supplemented to significant degrees by other institutional sources of funds. In summary, these funds provide a means to pursue the particulariy new and innovative initiatives, not generally funded by established sponsored research entities that potentiate Center-defining areas of scientific research.

Public Health Relevance

An NCl-designated Comprehensive Cancer Center, the UCCC is dedicated to the discovery of the nature of cancer and the development of more effective approaches to prevention, diagnosis and therapy. The requested Developmental funds provide flexibility to recruit faculty, fund pilot grants, and develop shared resources that strengthen the UCCC's research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616646
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$458,345
Indirect Cost
$155,376
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Harder, Bryan; Tian, Wang; La Clair, James J et al. (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56:1493-1500
Chen, Yufei; Anastassiadis, Konstantinos; Kranz, Andrea et al. (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell 31:755-770.e6
DeRyckere, Deborah; Lee-Sherick, Alisa B; Huey, Madeline G et al. (2017) UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res 23:1481-1492
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Neelakantan, Deepika; Zhou, Hengbo; Oliphant, Michael U J et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun 8:15773
Barón, Anna E; Kako, Severine; Feser, William J et al. (2017) Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol 12:1512-1523
Todd, Maria C; Langan, Thomas A; Sclafani, Robert A (2017) Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. J Cancer 8:190-198
Brown, Dustin G; Borresen, Erica C; Brown, Regina J et al. (2017) Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr 117:1244-1256
Haverkos, Bradley M; Abbott, Diana; Hamadani, Mehdi et al. (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221-228
Shearn, Colin T; Saba, Laura M; Roede, James R et al. (2017) Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. Free Radic Biol Med 113:280-290

Showing the most recent 10 out of 1448 publications